Skip to main content

Advertisement

Log in

l-Carnitine Treatment Reduces Steatosis in Patients with Chronic Hepatitis C Treated with α-Interferon and Ribavirin

  • Original Paper
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background Hepatic steatosis is a common presentation in patients with chronic hepatitis C. Interferon α exerts both antiviral and immunomodulating actions, and influences on lipid metabolism. The aim of our study was to test whether l-carnitine reduces steatosis in patients treated with interferon and ribavirin. Patients and methods A total of 70 patients were randomly assigned to receive either leucocyte IFN alpha at a dose of 3 MIU thrice a week plus 1,000 mg ribavirin per day for 12 months (group A) or IFN alpha and ribavirin at the same dose plus 2 g carnitine per day (group B). Results Comparison of the two treatments showed significant differences between the mean values of the following parameters at the end of the treatment: ALT −68 vs −95 IU/ml (P < 0.05), total cholesterol 0.08 vs −0.91 mmol/l (P <  0.05) and triglycerides +0.25 vs −20 mmol/l (P < 0.05); and at the follow-up: AST −35 vs −65 IU/ml (P < 0.05) and ALT −55 vs −84 IU/ml (P < 0.05). All values were lower in group B (IFN + Ribavirin + Carnitine) than in group A (IFN plus Ribavirin). When comparing those patients treated with IFN + ribavirin with those treated with IFN plus ribavirin plus carnitine, the response at the end of the treatment was 48% vs 56%, and the sustained response 39% vs 46%, respectively. Conclusions Combined treatment with l-carnitine, ribavirin and IFN alpha resulted in greater antihyperlipidaemic effects and than with ribavirin and IFN alpha alone. The results of this study suggest that l-carnitine may have a role among the reduction of steatosis strategies in patients with hepatitis C treated with IFN alpha and ribavirin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Barba G, Harper F, Harada T, Kohara M, Goulinet S, Matsuura Y, Eder G, Schaff Z, Chapman MJ, Miyamura T, Brechot C (1997) Hepatitis C Virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci U S A 94:1200–1205

    Article  PubMed  CAS  Google Scholar 

  2. Moriya K, Yotsuyanagi H, Shintani Y, Fujie H, Ishibashi K, Matsuura Y, Miyamura T, Koike K (1997) Hepatitis C Virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 78:1527–1531

    PubMed  CAS  Google Scholar 

  3. Garcia-Monzon C, Martin-Perez E, Iacono OL, Fernandez-Bermejo M, Majano Pl, Apolinario A, Larranaga E, Moreno-Otero R (2000) Characterization of pathogenetic and prognostic factors of non-alcoholic steatohepatitis associated with obesity. J Hepatol 33:716–724

    Article  PubMed  CAS  Google Scholar 

  4. Czaya AJ, Carpenter HA, Santrach PJ, Moore SB (1998) Host- and disease-specific factors affecting steatosis in chronic hepatitis C. J Hepatol 29:198–206

    Article  Google Scholar 

  5. Bach N, Thung SN, Shaffner F (1992) The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology 15:572–577

    Article  PubMed  CAS  Google Scholar 

  6. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, Khalil L, Turpin G, Opolon P, Poynard T (2000) Liver fibrosis in overweight patients. Gastroenterology 118:1117–1123

    Article  PubMed  CAS  Google Scholar 

  7. Angulo P, Keach JC, Batts KP, Lindor KD (1999) Independent predictors of liver fibrosis in patients with non-alcoholic steatohepatitis. Hepatology 30:1356–1362

    Article  PubMed  CAS  Google Scholar 

  8. Alter MJ, Kruszon-Moran D, Nainan OV, Mcquillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS (1999) The prevalence of hepatitis C virus infection in the United States 1988 through 1994. N Engl J Med 341:556–562

    Article  PubMed  CAS  Google Scholar 

  9. Lauer GM, Waker BD (2001) Hepatitis C Virus infection. N Engl J Med 345:41–52

    Article  PubMed  CAS  Google Scholar 

  10. Malaguarnera M, Giugno I, Trovato BA, Panebianco MP, Siciliano R, Ruello P (1995) Lipoprotein (A) concentration in patients with chronic active C before and after interferon treatment. Clin Ther 17:721–728

    Article  PubMed  CAS  Google Scholar 

  11. Malaguarnera M, Giugno I, Ruello P, Pistone G, Restuccia S, Trovato BA (1996) Effects of interferon on blood lipids. Clin Drug Invest 11:43–48

    Article  CAS  Google Scholar 

  12. Naeem M, Bacon BR, Mistry B, Britton RS, Di Bisceglie AM (2001) Changes in serum lipoprotein profile during interferon therapy in chronic hepatitis C. Am J Gastroenterol 96:2468–2472

    Article  PubMed  CAS  Google Scholar 

  13. Rebouche CJ, Seim H (1998) Carnitine metabolism and its regulation in microorganisms and mammals. Ann Rev Nut 18:39–61

    Article  CAS  Google Scholar 

  14. Romano M, Malaguarnera M, Vinci M, Batticani S, Consoli G, Navarria G (1996) Incidence and ultrasonographic patterns of hepatic steatosis in the elderly. Arch Gerontol Geriatr 5:313–316

    Article  Google Scholar 

  15. Malaguarnera M, Restuccia N, Di Fazio I, Panebianco MP, Gulizia G, Giugno I (1999) Fish oil treatment of interferon-alpha-induced dyslipidemia: study in patients with chronic hepatitis C. Biodrugs 11:285–291

    Article  PubMed  CAS  Google Scholar 

  16. Malaguarnera M, Maugeri D, Saraceno B, Romano M, Neri S, Rapisarda R, Pistone G (2002) Effects of carnitine on biochemical responses in patients with chronic hepatitis C treated with interferon-Α. Clin Drug Invest 22:443–448

    Article  CAS  Google Scholar 

  17. Malaguarnera I, Di Fazio S, Restuccia G, Pistone N, Restuccia BA (1998) Trovato efficacy of different schedules in the management of chronic hepatitis C with interferon-α. Ann Med 30:213–217

    Article  PubMed  CAS  Google Scholar 

  18. Alberti A, Benvegnu L (2003) Management of hepatitis C. J Hepatol 38:S104–118

    Article  PubMed  Google Scholar 

  19. Stuyver L, Wyseur A, Van Arnhem W, Hernandez F, Maertens G (1996) Second-generation line probe assay for hepatitis C virus genotyping. J Clin Microbiol 34:2259–2266

    PubMed  CAS  Google Scholar 

  20. Simmonds P, Alberti P, Halter HJ, Bonino F, Bradley DW, Brechot C, Brouwer JT (1994) A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 19:1321–1324

    Article  PubMed  CAS  Google Scholar 

  21. Knodell R, Ishack K, Black W (1981) Formulation and application of numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1:431–435

    Article  PubMed  CAS  Google Scholar 

  22. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR (1999) Non-alcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94:2467–2474

    Article  PubMed  CAS  Google Scholar 

  23. Deufel T (1990) Determination of l-carnitine in biological fluids and tissues. J Clin Chem Clin Biochem 28:307–311

    PubMed  CAS  Google Scholar 

  24. Malaguarnera L, Rosa MD, Zambito AM, Dell’ombra N, Marco RD, Malaguarnera M (2006) Potential role of chitotriosidase gene in nonalcoholic fatty liver disease evolution. Am J Gastroenterol 101(9):2060–2069 Epub 2006 Jul 18

    Article  PubMed  CAS  Google Scholar 

  25. Malaguarnera L, Di Rosa M, Zambito Am, Dell’ombra N, Nicoletti F, Malaguarnera M (2006) Chitotriosidase gene expression in Kupffer cells from patients with non-alcoholic fatty liver disease. Gut 55(9):1313–1320 Epub 2006 Jul 6

    Article  PubMed  CAS  Google Scholar 

  26. Thomssen R, Bonk S, Propfee C, Heerman KH, Kochel HG, Uy A (1992) Association of hepatitis C virus in human sera with beta lipoprotein. Med Microbiol Immunol 181:293–300

    Article  PubMed  CAS  Google Scholar 

  27. Rubbia-Brandt L, Quadri R, Abid K, Giostra E, Male PJ, Mentha G, Spahr L, Zarski JP, Borisch B, Hadengue A, Negro F (2000) Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype. J Hepatol 33:106–115

    Article  PubMed  CAS  Google Scholar 

  28. Kumar D, Farrell GC, Fung C, George J (2002) Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response. Hepatology. 36:1266–1272

    Article  PubMed  Google Scholar 

  29. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G (2001) Steatosis accelerates the progression of liver damage of chronic hepatitis c patients and correlates with specific hcv genotype and visceral obesity. Hepatology 33:1358–1364

    Article  PubMed  CAS  Google Scholar 

  30. Shinohara E, Yamashita S, Kihara S, Hirano K, Ishigami M, Arai T, Nozaki S, Kameda-Takemura K, Kawata S, Matsuzawa Y (1997) Interferon alpha induces disorder of lipid metabolism by lowering postheparin lipases and cholesteryl ester transfer protein activities in patients with chronic hepatitis C. Hepatology 25:1502–1506

    Article  PubMed  CAS  Google Scholar 

  31. Dixon RM, Borden EC, Keim NL, Anderson S, Spennetta TL, Tormey DC, Shrago E (1984) Decreases in serum high-density lipoprotein cholesterol and total cholesterol resulting from naturally produced and recombinant DNA-derived leukocyte interferons. Metabolism 33:400–404

    Article  PubMed  CAS  Google Scholar 

  32. Massaro ER, Borden EC, Hawkins MJ, Wiebe DA, Shrago E (1986) Effects of recombinant interferon-alpha 2 treatment upon lipid concentrations and lipoprotein composition. J Interferon Res 6:655–665

    PubMed  CAS  Google Scholar 

  33. Maebashi M, Kawamura N, Sato M, Imamura A, Yoshinaga K (1978) Lipid-lowering effect of carnitine in patients with type-IV hyperlipoproteinaemia. Lancet 2:805–807

    Article  PubMed  CAS  Google Scholar 

  34. Khan L, Bamji MS (1979) Tissue carnitine deficiency due to dietary lysine deficiency: triglyceride accumulation and concomitant impairment in fatty acid oxidation. J Nutr 109:24–31

    PubMed  CAS  Google Scholar 

  35. Richter V, Rassoul F, Schulz G, Sittner WD, Seim H, Loster H, Rotzsch W (1987) Carnitine and experimental carbohydrate-induced hyperlipoproteinemia. Arch Int Pharmacodyn Ther 290(1):138–144

    PubMed  CAS  Google Scholar 

  36. Feng Y, Guo C, Wei J, Yang J, Ge Y, Gao L (2001) Necessity of carnitine supplementation in semistarved rats fed a high-fat diet. Nutrition 17(7–8):628–631

    Article  PubMed  CAS  Google Scholar 

  37. Malaguarnera M, Pistone G, Neri S, Romano M, Brogna A, Musumeci S (2004) Interleukin-2 plus ribavirin versus interferon-alpha-2b plus ribavirin in patients with chronic hepatitis C who did not respond to previous interferon-alpha-2b treatment. Biodrugs 18:407–413

    Article  PubMed  CAS  Google Scholar 

  38. Famularo G, De Simone C (1995) A new era for carnitine? Immunol Today 16:211–213

    Article  PubMed  CAS  Google Scholar 

  39. Sougero C, Joo M, Chianese-Bulock KA, Nguyen DT, Tung K, Hahn V (2002) Hepatitis C virus core protein leads to immune suppression and liver damage in a transgenic murine model. J Virol 76:9345–9354

    Article  CAS  Google Scholar 

  40. Lederblad G (1976) Plasma carnitine and body composition. Clin Chim Acta 67:207–212

    Article  Google Scholar 

  41. Lysiak W, Lilly K, Dilisa F, Toth PP, Bieber LL (1988) Quantitation of the effect of l-carnitine on levels of acid-soluble short-chain acyl-CoA and CoASH in rat heart and liver mitochondria. J Biol Chem 263:1151–1155

    PubMed  CAS  Google Scholar 

  42. Feng V, Suo CJ, Wei JV et al (2000) The impact of fat rich feeding on carnitine and lipid metabolism in half-starved rats. Chin J Clin Nutr 8:96–101

    Google Scholar 

  43. Lewis JA, Huq A, Najarro P (1996) Inhibition of mitochondrial function by interferon. J Biol Chem 271:13184–13190

    Article  PubMed  CAS  Google Scholar 

  44. Kraemer WJ, Volek JS, French DN, Rubin MR, Sharman MJ, Gomez AL, Ratamess NA, Newton RU, Jemiolo B, Craig BW, Hakkinen K (2003) The effects of l-carnitine l-tartrate supplementation on hormonal responses to resistance exercise and recovery. J Strength Cond Res 17(3):455–462. Pmid: 12930169

    Article  PubMed  Google Scholar 

  45. Fernandez-Checa JC, Kaplowitz N, Garcia-Ruiz C, Colell A, Miranda M, Mari M, Ardite E, Morales A (1997) Gsh transport in mitochondria: defense against tnf-induced oxidative stress and alcohol-induced defect. Am J Physiol 273(1 Pt 1):G7–17. Review. Pmid: 9252504

    PubMed  CAS  Google Scholar 

  46. Quillet-Mary A, Jaffrezou JP, Mansat V, Bordier C, Naval J, Laurent G (1997) Implication of mitochondrial hydrogen peroxide generation in ceramide-induced apoptosis. J Biol Chem 272(34):21388–21395. Pmid: 9261153

    Article  PubMed  CAS  Google Scholar 

  47. Perez-Carreras M, Del Hoyo P, Martin MA, Rubio JC, Martin A, Castellano G, Colina F, Arenas J, Solis-Herruzo JA (2003) Defective hepatic mitochondrial respiratory chain in patients with non-alcoholic steatohepatitis. Hepatology 38:999–1007

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mariano Malaguarnera.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Romano, M., Vacante, M., Cristaldi, E. et al. l-Carnitine Treatment Reduces Steatosis in Patients with Chronic Hepatitis C Treated with α-Interferon and Ribavirin. Dig Dis Sci 53, 1114–1121 (2008). https://doi.org/10.1007/s10620-007-9983-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-007-9983-1

Keywords

Navigation